Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CNS Pharmaceuticals SEC filings document the regulatory record for a clinical-stage pharmaceutical company developing therapies for brain and central nervous system cancers. Its filings cover material-event reports, Regulation FD investor presentations, operating and financial updates, clinical and regulatory disclosures, and capital-structure information for its Nasdaq-listed common stock.
The company’s proxy and 8-K filings also describe governance matters, annual-meeting votes, equity-plan amendments, officer appointments, employment agreements and related compensation arrangements. These disclosures frame the company’s formal reporting around pipeline strategy, corporate leadership, stockholder approvals and public-company controls.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 561,148 shares of CNS Pharmaceuticals common stock, representing 9.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), exercises shared voting and dispositive power over these shares; Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The filing states the Master Fund is the direct holder and that it disclaims beneficial ownership to the extent it cannot vote or dispose of the securities under its investment management agreement.